Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales

Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels

(2020) Eric Ransom et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase–Producing Enterobacterales During a Regional Outbreak

(2020) Marco Falcone et al.   Open Forum Infectious Diseases

Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations

(2018) Jason M Pogue et al.   CLINICAL INFECTIOUS DISEASES

Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

(2017) Evelyn Shaw et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroActivity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

(2015) Douglas J. Biedenbach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli

(2015) Shawn Vasoo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA